EA201790400A1 - Зонды для визуализации белка хантингтина - Google Patents

Зонды для визуализации белка хантингтина

Info

Publication number
EA201790400A1
EA201790400A1 EA201790400A EA201790400A EA201790400A1 EA 201790400 A1 EA201790400 A1 EA 201790400A1 EA 201790400 A EA201790400 A EA 201790400A EA 201790400 A EA201790400 A EA 201790400A EA 201790400 A1 EA201790400 A1 EA 201790400A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hantingtin
visualization
probes
protein
compound
Prior art date
Application number
EA201790400A
Other languages
English (en)
Other versions
EA039923B1 (ru
Inventor
Селиа Домингез
Джон Витяк
Джонатан Бард
Алекс Киселев
Кристофер Джон Браун
Майкл Эдвард Прайм
Питер Дэвид Джонсон
Дэниел Кларк-Фрю
Original Assignee
Сиэйчдиай Фаундэйшн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэйчдиай Фаундэйшн, Инк. filed Critical Сиэйчдиай Фаундэйшн, Инк.
Publication of EA201790400A1 publication Critical patent/EA201790400A1/ru
Publication of EA039923B1 publication Critical patent/EA039923B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к визуализирующим агентам, содержащим соединение формулы (I) или его фармацевтически приемлемую соль, и способам их применения.
EA201790400A 2014-08-29 2015-08-28 Зонды для визуализации белка хантингтина EA039923B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043590P 2014-08-29 2014-08-29
PCT/US2015/047401 WO2016033440A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
EA201790400A1 true EA201790400A1 (ru) 2017-09-29
EA039923B1 EA039923B1 (ru) 2022-03-28

Family

ID=55400645

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790400A EA039923B1 (ru) 2014-08-29 2015-08-28 Зонды для визуализации белка хантингтина

Country Status (20)

Country Link
US (2) US11104691B2 (ru)
EP (1) EP3197277B1 (ru)
JP (1) JP6754353B2 (ru)
KR (1) KR102410733B1 (ru)
CN (1) CN107105667B (ru)
AU (2) AU2015308769A1 (ru)
BR (1) BR112017004140B1 (ru)
CA (1) CA2959533C (ru)
DK (1) DK3197277T3 (ru)
EA (1) EA039923B1 (ru)
ES (1) ES2905095T3 (ru)
HR (1) HRP20220001T1 (ru)
HU (1) HUE057702T2 (ru)
IL (1) IL250802B (ru)
MX (1) MX2017002702A (ru)
PL (1) PL3197277T3 (ru)
PT (1) PT3197277T (ru)
SG (1) SG11201701592SA (ru)
SI (1) SI3197277T1 (ru)
WO (1) WO2016033440A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3186241T1 (sl) 2014-08-29 2021-03-31 Chdi Foundation, Inc. Sonde za slikanje Huntingtonovega proteina
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
ES2818107T3 (es) 2014-08-29 2021-04-09 Chdi Foundation Inc Sondas para obtener imágenes de la proteína huntingtina
SG11201701592SA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
JP6944929B2 (ja) 2015-08-28 2021-10-06 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
US20190381030A1 (en) * 2017-10-12 2019-12-19 University Of Kansas Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using yel002/bcn057
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
EP3966215A1 (en) 2019-05-09 2022-03-16 F. Hoffmann-La Roche AG Synthesis of labeled imidazo[1,2-a]pyrimidines
CN114773312B (zh) * 2021-10-29 2024-03-26 北京鑫诺康桥药物研究有限公司 一种盐酸阿罗洛尔中间体的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2004265174A1 (en) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. Probe for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles.
AU2007261985B2 (en) * 2006-06-21 2012-04-19 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
EP2098523A4 (en) * 2006-11-17 2011-09-21 Nihon Mediphysics Co Ltd NEW, AMYLOID-AFFINE COMPOUNDS
KR20090083414A (ko) * 2006-11-30 2009-08-03 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
KR20090101469A (ko) 2007-01-22 2009-09-28 아스트라제네카 아베 신규 헤테로아릴 치환된 이미다조〔１，２­ａ〕피리딘 유도체
JPWO2009057577A1 (ja) * 2007-10-30 2011-03-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物の使用及び製造方法
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
KR20110046503A (ko) * 2008-07-24 2011-05-04 지멘스 메디컬 솔루션즈 유에스에이, 인크. Ａｄ 병인을 확인하기에 유용한 영상화제
DK2338059T3 (en) 2008-09-23 2015-06-15 Wista Lab Ltd Ligands for aggregated tau molecules
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
CA2836872A1 (en) * 2011-05-20 2012-11-29 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
JP5167436B2 (ja) * 2011-06-24 2013-03-21 日本メジフィジックス株式会社 新規アミロイド親和性化合物
JP2013237655A (ja) 2012-05-17 2013-11-28 Kyoto Univ コンフォメーション病診断用分子プローブ
RU2015118985A (ru) * 2012-11-14 2017-01-10 Ф. Хоффманн-Ля Рош Аг Производные имидазопиридина
HUE035966T2 (en) 2013-03-14 2018-05-28 Galapagos Nv Compounds and compositions for the treatment of inflammatory diseases
KR101770532B1 (ko) 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
ES2818107T3 (es) 2014-08-29 2021-04-09 Chdi Foundation Inc Sondas para obtener imágenes de la proteína huntingtina
SI3186241T1 (sl) 2014-08-29 2021-03-31 Chdi Foundation, Inc. Sonde za slikanje Huntingtonovega proteina
SG11201701592SA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
JP6944929B2 (ja) 2015-08-28 2021-10-06 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ

Also Published As

Publication number Publication date
MX2017002702A (es) 2017-10-23
ES2905095T3 (es) 2022-04-07
JP2017529340A (ja) 2017-10-05
CN107105667B (zh) 2021-08-17
CA2959533C (en) 2023-03-07
US11851446B2 (en) 2023-12-26
AU2019283999A1 (en) 2020-01-23
HUE057702T2 (hu) 2022-05-28
BR112017004140B1 (pt) 2023-01-10
AU2015308769A1 (en) 2017-03-23
WO2016033440A1 (en) 2016-03-03
PT3197277T (pt) 2022-02-01
KR20170047303A (ko) 2017-05-04
KR102410733B1 (ko) 2022-06-20
IL250802B (en) 2020-08-31
JP6754353B2 (ja) 2020-09-09
EA039923B1 (ru) 2022-03-28
US11104691B2 (en) 2021-08-31
DK3197277T3 (da) 2022-01-31
EP3197277A4 (en) 2018-04-18
PL3197277T3 (pl) 2022-04-04
IL250802A0 (en) 2017-04-30
SG11201701592SA (en) 2017-03-30
SI3197277T1 (sl) 2022-04-29
US20170283439A1 (en) 2017-10-05
EP3197277B1 (en) 2021-12-22
CN107105667A (zh) 2017-08-29
BR112017004140A2 (pt) 2017-12-12
US20210380608A1 (en) 2021-12-09
AU2019283999B2 (en) 2021-07-22
EP3197277A1 (en) 2017-08-02
HRP20220001T1 (hr) 2022-04-01
CA2959533A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201792021A1 (ru) Ингибитор jak
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201892430A1 (ru) Синтез индазолов
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
EA201691541A1 (ru) Новые анти-baff антитела
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201790570A1 (ru) Модуляторы р2х7
MX2018002338A (es) Sondas para formar imagenes de proteina de huntingtina.
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида